Tau brain imaging with PET scans in people at risk for Alzheimer's disease
Studies tau protein build-up in the brain using a PET scan in adults.
Plain-language title generated from the registry record
Registry title: Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population
Key facts
- Where
- Barcelona, SpainSee the site
- Phase
- Phase 2
Where in Spain
- Barcelonabeta Brain Research CenterBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Barcelonabeta Brain Research Center
- Trial code
- NCT04482660EU 2024-516209-21-00
- Record updated
- 31 March 2026
- Original description
Characterize tau tracer retention as a function of amyloid levels transversally and longitudinally.Read full original descriptionShow less
Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population
Characterize tau tracer retention as a function of amyloid levels transversally and longitudinally.
Inclusion: To sign the study informed consent form approved by the corresponding authorities; Men and women that have participated in a BBRC-sponsored study, including the ALFA project (STUDY 45-65 FPM/2012), the ALFA+ cohort study (ALFA - FPM - 0311), the ALFA cognition study (ALFAcognition/BBRC2017), the BarcelonaBeta Dementia Prevention Research Clinic study (BBRC-DemPrev-2018) or the βETA-AARC study (β-AARC_BBRC2021); Age between 45 and 80 years at the moment of inclusion in the BBRC-sponsored studies specified above; Participants with an available cerebral MRI within the last 12 months not suggestive of radiological incidental findings constituting an exclusion criterion; Known cognitive status based on the cognitive workup of the BBRC-sponsored studies specified above. Cognitive status may have been determined within the last 12 months; Known AB and tau status; Good knowledge of the language and being literate; Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition.
Exclusion: Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study; Active drug or alcohol abuse, as assessed in the BBRC-sponsored studies specified above; Previous intolerance to PET studies or known hypersensitivity to 18F-RO6958948; Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia and bipolar disorder, as assessed in the BBRC-sponsored studies specified above; Visual and/or hearing impairment; History of encephalitis, ictus or seizures excluding feverish convulsions during childhood, as assessed in the BBRC-sponsored studies specified above; Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumour (metastasis/brain cancer) as verified by MRI; Clinically relevant renal or hepatic insufficiency; Any other clinically important condition that may jeopardize the study or be dangerous for the participant; Being pregnant or breast-feeding.